Sugi Predict

Sugi Predict / Compounds / SCHEMBL1742298

SCHEMBL1742298

SCHEMBL1742298

COc1ccc(-c2ccc(Cl)nn2)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.51
▸ NPC1 O15118 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CYP17A1 P05093 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ PDGFRB P09619 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ MET P08581 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744281 0.85 MEN1 (0.53) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL13511832 0.83 MAPT (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL11624499 0.81 MAPT (0.51) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL9183598 0.80 PDE4D (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL9188551 0.80 PDE4D (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL9183215 0.78 SMN1; SMN2 (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL9186261 0.78 PDE4B (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL9183532 0.78 SMN1; SMN2 (0.48) ALDH1A1NPC1SMN1; SMN2MEN1KMT2A
SCHEMBL9180769 0.78 SMN1; SMN2 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL9186302 0.77 XDH (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 — — US disclosed
EP-1827434-B1 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC (US) 2014-01-15 — — EP disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 — — US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 — — US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 — — EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 — — EP disclosed
US-7652009-B2 Substituted heterocycles and methods of use AMGEM INC. (US) 2010-01-26 — — US disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 — — US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 — — US disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 — — EP disclosed
EP-1827434-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER Amgen Inc. (US) 2007-09-05 — — EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 — — WO disclosed
US-20060252777-A1 Substituted heterocycles and methods of use AMGEN INC. (US) 2006-11-09 — — US disclosed
WO-2006060318-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC. (US) 2006-06-08 — — WO disclosed
EP-1474401-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2004-11-10 — — EP disclosed
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC 2003-12-25 — — US disclosed
WO-2003066604-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2003-08-14 — — WO disclosed
US-4515791-A Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents AMERICAN CYANAMID COMPANY (US) 1985-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 ALDH1A1 4021/4885NPC1 2646/4885RAB9A 4607/4885
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HRH3, HRH2, HRH4 ALDH1A1 2719/4885NPC1 2195/4885RAB9A 3350/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 ALDH1A1 4021/4885NPC1 2646/4885RAB9A 4607/4885
US-20060252777-A1 Substituted heterocycles and methods of use HGF, HGFAC, MET ALDH1A1 95/4885NPC1 445/4885RAB9A 1707/4885
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HRH3, HRH2, HRH4 ALDH1A1 2719/4885NPC1 2195/4885RAB9A 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.